Charlotte Thompson
Adult Health · Bozeman, MTNPI 1538614946
Payments from drug & device makers
What this record shows
Livanova USA, Inc. accounts for 72.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $1,958 and has fallen 86.6% since, to $263 in 2025.
Across 40 payments — averaging $65.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- AbbVie$364
- Teva Pharmaceuticals USA, Inc.$156
- Bristol Myers Squibb$93
- Pfizer$38
- Johnson & Johnson$31
- plus $49 from 2 others
What the payments were for
- Travel & lodging$1,40354%
- Food & beverage$1,21446%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 7 | $1,886 |
| AbbVie | 16 | $364 |
| Teva Pharmaceuticals USA, Inc. | 6 | $156 |
| Bristol Myers Squibb | 6 | $93 |
| Pfizer | 2 | $38 |
| Johnson & Johnson | 1 | $31 |
| Vertex | 1 | $25 |
| Argenx US, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,793
How this compares
$2,617 in reported general payments places this provider in the 80th percentile of 27 adult health providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GilenyaFingolimod Hcl | 12 | $125,532 |
| TecfideraDimethyl Fumarate | 11 | $98,059 |
| CopaxoneGlatiramer Acetate | 12 | $68,870 |
| Emgality PenGalcanezumab-Gnlm | 33 | $22,893 |
| Glatiramer Acetate | 11 | $21,425 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $20,137 |
| UbrelvyUbrogepant | 17 | $16,913 |
| Rasagiline Mesylate | 20 | $7,080 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 56 | $4,018 |
| Lamotrigine | 74 | $2,457 |
| Oxcarbazepine | 23 | $2,359 |
| Candesartan Cilexetil | 11 | $1,408 |
| Primidone | 22 | $1,355 |
| Carbamazepine ErCarbamazepine | 17 | $1,258 |
| Levetiracetam | 42 | $989 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $156 | $68,87012 claims |
| AbbVieUbrelvy | $364 | $16,91317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 27 adult health providers in Montana.
Other adult health in Bozeman
- Margaret HammerslaBozeman$2K
- Ami ShetlerBozeman$207
- Alice RunningBozeman$111
- Tauna JefferyBillings$4K
- Brittany SilversBillings$4K
- Joslyn ThompsonBillings$3K
- Karista WalshBillings$3K
- Janice OstermillerBillings$3K
- Sarah RobertsMissoula$2K
- Gregory HubbsBillings$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.